This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
JCI vs. AXON: Which Stock Is the Better Value Option?
by Zacks Equity Research
JCI vs. AXON: Which Stock Is the Better Value Option?
Axon Enterprise (AXON) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Axon (AXON) delivered earnings and revenue surprises of 72.73% and 26.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Industrial Stocks' Aug 5 Q2 Earnings Roster: BLL, AXON & More
by Madhurima Das
A brief look at what factors might drive the Q2 results of stocks like Ball Corp (BLL), Axon Enterprise (AXON), Terminix Global (TMX), Resideo Technologies (REZI) and Alarm.com Holdings (ALRM).
Axon Enterprise (AXON) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Axon (AXON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axon Enterprise (AXON) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Axon (AXON) delivered earnings and revenue surprises of 47.62% and 17.72%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Axon Enterprise (AXON) Q1 Earnings Expected to Decline
by Zacks Equity Research
Axon (AXON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Earnings Season Could Be Great for Axon Enterprise (AXON)
by Zacks Equity Research
Axon Enterprise (AXON) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights: Denbury, Axon Enterprise, Caterpillar, Scotts Miracle-Gro and Eastman Chemical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Denbury, Axon Enterprise, Caterpillar, Scotts Miracle-Gro and Eastman Chemical
Cyclical Sectors Gain Momentum in Early 2021: 7 Top Picks
by Nalak Das
We have narrowed down our search to seven cyclical stocks that have popped more than 10% year to date and still have upside left for 2021. These are: DEN, CFG, GS, AXON, EMN, CAT and SMG.
Flowserve (FLS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Flowserve's (FLS) Q4 earnings are likely to have gained from signs of recovery in end markets, solid backlog and cost-control actions. Low demand due to the pandemic might have marred its performance.
Ingersoll (IR) to Post Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Ingersoll Rand's (IR) Q4 earnings are likely to have gained from solid product portfolio, the Albin Pump buyout and cost-control actions. Unfavorable product mix might have marred its performance.
Axon Enterprise (AXON) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Axon (AXON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allegion (ALLE) Surpasses Q4 Earnings and Sales Estimates
by Zacks Equity Research
Allegion (ALLE) Q4 results reflect growth in sales and expansion in operating margin. Earnings for 2021 are predicted to decline year over year.
Allegion (ALLE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Allegion's (ALLE) Q4 earnings are likely to have gained from solid product demand, strong residential business & healthy backlog. Low demand in Korea and Australia might have marred its performance.
ADT or AXON: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADT vs. AXON: Which Stock Is the Better Value Option?
iRobot (IRBT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
iRobot's (IRBT) Q4 earnings are likely to have gained from solid product demand, the holiday season and strong sales channels. However, high costs and expenses might have marred its performance.
II-VI (IIVI) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
II-VI's (IIVI) Q2 earnings are likely to have gained from the solid product demand, the Finisar buyout and strong sales channels. However, high costs and expenses might have marred its performance.
Parker-Hannifin (PH) to Post Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
Strength in life science, semiconductor, rail and power end markets is expected to have boosted Parker-Hannifin's (PH) fiscal Q2 earnings. Soft automotive and oil and gas space might have been drags.
Emerson (EMR) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Emerson's (EMR) Q1 earnings are likely to have gained from solid medical, life science, & power end markets. Weak process & discrete end markets, and coronavirus-led woes might have played spoilsport.
Fortune Brands (FBHS) to Post Q4 Earnings: Beat in Store?
by Zacks Equity Research
Solid demand for decking products and strength in security business and plumbing businesses are expected to have aided Fortune Brands' (FBHS) Q4 earnings. High costs might have been a spoilsport.
Options Traders Expect Huge Moves in Axovant (AXON) Stock
by Zacks Equity Research
Investors need to pay close attention to Axovant (AXON) stock based on the movements in the options market lately.
Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study
by Zacks Equity Research
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition
by Zacks Equity Research
Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.
Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study
by Zacks Equity Research
Ultragenyx releases encouraging top-line data from the phase III study on UX007 in patients with LC-FAOD.
Radius Exceeds 2018 Financial Guidance, Provides Updates
by Zacks Equity Research
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.